Instilación intrapleural de activador tisular de plasminógeno y de deoxirribonucleasa recombinante humana en el empiema pleural. Visits. Download PDF. Se colocó un catéter en el extremo aórtico de la fístula y se instauró, a su través, tratamiento con activador recombinante tisular del plasminógeno (r-TPA) en. activator in vascular warning syndromesTrombólisis intravenosa con activador tisular del plasminógeno recombinante en los síndromes de alarma vascular☆.
|Published (Last):||20 January 2007|
|PDF File Size:||9.30 Mb|
|ePub File Size:||8.92 Mb|
|Price:||Free* [*Free Regsitration Required]|
The medical records of 8 newborn were reviewed in a retrospective study, of whom 7 were preterm with cardiac thrombi, and rTPA was used in all of them. The superior vena cava was the most frequent location, with a mean time of installation before the diagnosis of 12 days.
Si continua navegando, consideramos que acepta su uso. This item has received.
Are you a health professional able to prescribe or dispense drugs? From Monday to Friday from 9 a. Previous article Next article.
You can change the settings or obtain more information by clicking here. To improve our services and products, we use “cookies” own or third parties authorized to show advertising related to client preferences through the analyses of navigation customer behavior.
They received between 1 to 5 cycles with rTPA. In 4 patients complete recombinanet of the thrombus was achieved in a mean of 3. Print Send to a friend Export reference Mendeley Statistics.
Subscribe to our Newsletter. The incidence of cardiac thrombi in newborns has increased with the use of central venous catheters. The journal fully endorses the goals of updating knowledge and facilitating the acquisition of key developments in internal medicine dek to clinical practice.
Recombinant tissue plasminogen activator for the management of intracardiac thrombi in newborns. The patients included 4 males with a mean weight of gr.
Activador del plasminógeno tisular recombinante en el manejo de trombos cardiacos en recién nacidos
tislar SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field. Three patients received low molecular weight heparin prior to using rTPA. Nine issues are published each year, including mostly originals, reviews and consensus documents.
Continuing navigation will be considered as acceptance of this use. Thrombolysis with recombinant tissue plasminogen activator rTPA has been used as an alternative to heparin in life threatening giant thrombus and embolization. Subscriber If you already have your login data, please click here.
CiteScore measures average citations received per document published. There were no deaths or embolism. The Impact Factor measures the average number of citations received in a particular year by avtivador published in the journal during the two receding years. Intracardiac thrombi; Neonatal thrombolysis; Recombinant tissue plasminogen activator. SRJ is a prestige metric based on the idea that not all citations are the same. The aim of this study is to describe the response and complications related to the use of rTPA in the management of life- threatening cardiac thrombi in newborns.
There was a problem providing the content you requested
SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal’s impact. Four patients had intracranial haemorrhage grade I, without sequelae at follow-up. March Pages ee24 Pages